I9DN Analyst Ratings
Currently, no data available
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
I9DN Stock 12 Month Forecast
There Are No Analyst Ratings for DE:I9DN In The Last 3 Months.
| Highest Price Target― | Average Price Target― | Lowest Price Target― |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
I9DN Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Jefferies
€6.13
Buy
53.91%
Upside
Reiterated
12/11/25
We've written extensively about the cases (primer here). A positive outcome with MRNA would also de-risk the PFE case, which is slightly behind, and which has a larger revenue pool associated with it. judgment will be another catalyst in the near term. judgment and Daubert briefings have just wrapped up.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Jefferies
€6.13
Buy
53.91%
Upside
Reiterated
12/11/25
We've written extensively about the cases (primer here). A positive outcome with MRNA would also de-risk the PFE case, which is slightly behind, and which has a larger revenue pool associated with it. judgment will be another catalyst in the near term. judgment and Daubert briefings have just wrapped up.
Best Analysts Covering Arbutus Biopharma
3 Months
Success Rate
1/3 ratings generated profit
Average Return
-7.67%
Copying Dennis Ding's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -7.67% per trade.
1 Year
Success Rate
2/3 ratings generated profit
Average Return
+3.93%
Copying Dennis Ding's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +3.93% per trade.
2 Years
Success Rate
2/3 ratings generated profit
Average Return
+7.23%
Copying Dennis Ding's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +7.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
I9DN Analyst Recommendation Trends
Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
0
0
Each month's total comprises the sum of three months' worth of ratings.
I9DN Stock Forecast FAQ
What is DE:I9DN’s average 12-month price target, according to analysts?
Currently, no data Available
What is DE:I9DN’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:I9DN, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Arbutus Biopharma a Buy, Sell or Hold?
Currently, no data Available
What is Arbutus Biopharma’s share price target?
Currently, no data Available
What do analysts say about Arbutus Biopharma?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of Arbutus Biopharma?
To buy shares of DE:I9DN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.